.png){kind=icon}
Covid-19测试，药物开发，诊断和设备解决方案
Whether you are developing a COVID-19 assay, a vaccine to prevent patients from getting COVID-19, an antiviral or a treatment to mitigate the severe immunological response (cytokine storm) associated with COVID-19, we can partner with you to provide critical drug development and diagnostic services to address the global pandemic.
从诊断到交付的发展，我们正在进行使您的速度增加到市场，并加速全球需求的Covid-19治疗方案。了解我们如何共同努力，帮助您实现攻击目标，最终会满足患者的迫切需求。
视频：The moment COVID-19 hit, LabCorp’s nearly 65,000 employees began to fight the virus with innovative testing and treatment solutions. Through a focus on science, we have played a critical role in improving outcomes for patients, providers, and our global community.Play video。
我们可以一起提供无与伦比的加速。这是我们将如何：
能够与我们的Covid-19回复团队进行高度协作的伙伴关系
A dedicated and highly coordinatedCOVID-19 Response Team将帮助您联系到合适的人员和监管机构，以加快您的发展。
Seamlessly integrate cross-functional expertise for your end-to-end development
Transition quickly between phases and eliminate risky handoff points that can impact your timeline. As you move to the next phase, our breadth of coordinated services extend your team’s scientific and medical expertise as you move ahead to the next phase of your COVID-19 development journey.
Apply diagnostic insights and proprietary patient data to recruit for clinical studies
灵活性，亮度和无与伦比的患者见解对于Covid-19测试和药物开发至关重要。优化您的招聘策略with unparalleled patient and investigator site data and transformative technologies to enable study design, patient recruitment, forecasting, site selection and study monitoring.
Covid-19开发能力
在对抗Covid-19的斗争中应用Covance和Labcorp优势
No other organization can offer this breadth of coordinated services or match our global reach
药物开发与诊断能力
- LabCorp Patient Direct enables faster recruitment of LabCorp-tested COVID-19 patients
- 访问Labcorp测试的Covid-19患者的患者样品和数据
- 实验室测定和加急的测定验证
全球疫苗和传染病经验
- Critical care inpatient and outpatient experience
- 在过去5年中经验超过700种传染病试验和超过150例疫苗试验（见中央实验室测试and临床试验）
- 在过去5年中超过250件疫苗和抗病毒研究的经验（见nonclinical testing）
专用的Covid-19响应团队
- 动员，致力于Covid-19研究项目团队
- 非临床通过IV期药物开发使我们能够降低研究之间的过渡时间
- Cross-functional, experienced, rapid-response team meets daily to focus on client requests/ideas
Accelerated study startup & assay development
- 制定的世卫组织议定书和专用医疗作家的协议时间表减少了66％
- Database creation accelerated
- 能够通过远程监控Xcellerate®平台
患者参与和分散试验
- Voice of patient survey for COVID-19 trials
- 来自Labcorp Covid-19测试的数据允许快速患者识别
- Reduction of on-site visits through eConsent, home-health nurses, tele-health, etc.
- Patient safety monitoring and call centers
与监管机构的关系
- Frequent interactions with MHRA and FDA on new development programs
- Experience interacting with the FDA CTAP group
医疗装置& Diagnostics experience
- 过去5年来拥有500多种医疗设备和诊断研究的经验和超过5000名调查员站点
- 合同研究产品的广度包括从监管咨询到临床前，临床和商业化服务的整个产品开发生命周期yaboapp体育官网
#WeAreInThisTogether
Covance andLabCorp独特地定位于与您合作，提供关键的服务，以便以药物开发和诊断能力组合解决全球Covid-19大流行。
我们在一起。。。
- 通过发展来降低死亡率antiviral treatments。
- 通过发展来降低死亡率treatments to减轻严重的免疫反应在一些患者中，即在一些Covid-19感染期间引起的细胞因子风暴。
- 防止人们通过covid-19通过vaccine development。
- 提供对患者样品的访问，并根据我们的诊断Covid-19测试（包括超过20％的美国人口）直接访问患者，以评估有活性感染的患者，并确定对病毒的免疫应答。